The Amnestic Disorders Therapeutics Market is seeing increasing interest as memory disorders become a greater healthcare concern worldwide. The market is estimated at USD 2.1 billion in 2025 and is forecast to reach USD 3.8 billion by 2035, with a CAGR of 6.0% from 2026 to 2035.

The treatment landscape is becoming more technology-driven, with pharmaceutical research supported by advances in neuropharmacology, personalized medicine, and diagnostic tools. Researchers are also exploring biomarkers and data-driven methods that could help identify patients and treatments more accurately.

Medication remains a central treatment approach, while psychotherapy, cognitive rehabilitation, and supportive therapy offer additional ways to manage the broader effects of memory disorders. The market addresses conditions such as Alzheimer’s disease, traumatic brain injury, and substance-induced amnesia.

North America is expected to maintain a leading position, supported by advanced medical infrastructure and substantial research investment. Europe has strong treatment and diagnostic capabilities, while Asia-Pacific is positioned for continued expansion through improving healthcare access and rising expenditure.

Emerging opportunities include AI-enabled diagnosis, precision medicine, digital therapy, telehealth, and cognitive rehabilitation technologies. As understanding of memory disorders improves, the market could move toward more personalized treatment combinations that address pharmaceutical, cognitive, and supportive care needs.